DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Colorectal Carcinoma

Interventions: Drug: Cadonilimab
Drug: FOLFOX regimen

First Posted Date: 2023-12-04

Last Posted Date: 2023-12-04

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 170

Registration Number: NCT06154538

Locations: 🇨🇳
Cancer Hospital/ National Cancer Center, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients

Phase 3

Not yet recruiting

Conditions: Cancer
Thrombosis, Venous
Catheter Complications

Interventions: Drug: Edoxaban

First Posted Date: 2023-11-29

Last Posted Date: 2023-11-29

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 366

Registration Number: NCT06149533

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Early Phase 1

Recruiting

Conditions: Relapsed Solid Tumors
Refractory Solid Tumors

Interventions: Biological: KSX01-TCRT cell therapy

First Posted Date: 2023-11-29

Last Posted Date: 2025-03-26

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 12

Registration Number: NCT06150365

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)

Not Applicable

Recruiting

Conditions: Rectal Cancer

Interventions: Procedure: Dissection of the No.253 lymph node
Procedure: Omitting the dissection of the No.253 lymph node

First Posted Date: 2023-11-27

Last Posted Date: 2025-03-26

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 1384

Registration Number: NCT06146946

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Chaoyang district, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China

and more 5 locations

Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer

Recruiting

Conditions: Colorectal Cancer
Lymph Node Metastasis

Interventions: Procedure: Laparoscopic colorectal surgery

First Posted Date: 2023-11-18

Last Posted Date: 2023-11-18

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 3000

Registration Number: NCT06135571

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, Beijng, China
🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 1 locations

Prognosis Stratification for pT4bN0M0 Colorectal Cancer Following Multivisceral Resection

Completed

Conditions: Colorectal Cancer

First Posted Date: 2023-11-03

Last Posted Date: 2023-11-03

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 172

Registration Number: NCT06115837

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer

Recruiting

Conditions: Locally Recurrent Colorectal Cancer

Interventions: Procedure: salvage surgery

First Posted Date: 2023-11-02

Last Posted Date: 2023-11-02

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 500

Registration Number: NCT06114420

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Phase 3

Recruiting

Conditions: Esophageal Neoplasms

Interventions: Drug: TP or PF regimen depended on investigator's choice.
Radiation: Radiation
Biological: PD-1 inhibitor

First Posted Date: 2023-10-17

Last Posted Date: 2024-07-16

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 436

Registration Number: NCT06086457

Locations: 🇨🇳
Cancer hospital, CAMS, Beijing, Beijing, China

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

Phase 2

Recruiting

Conditions: Thyroid Cancer
Surgery
Recurrence

Interventions: Drug: Thyroxine

First Posted Date: 2023-10-17

Last Posted Date: 2023-10-17

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 140

Registration Number: NCT06087068

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Phase 2

Recruiting

Conditions: Esophageal Neoplasm Metastatic
Esophageal Cancer Stage IVb

Interventions: Drug: TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
Biological: PD-1 inhibitor
Radiation: Salvage Radiation
Radiation: Consolidation Radiation

First Posted Date: 2023-10-16

Last Posted Date: 2024-06-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 120

Registration Number: NCT06084897

Locations: 🇨🇳
Cancer hospital, CAMS, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy